How does ensidipine accurately attack IDH2 mutations in AML?

Ensidipine, as a cutting-edge therapeutic drug, provides a powerful therapeutic weapon for patients suffering from acute myeloid leukemia (AML) and carrying IDH2 gene mutations. The core of its therapeutic strategy is to precisely target intracellular isocitrate dehydrogenase 2 (IDH2), an enzyme that plays a key role in mitochondria.

Specifically, ensidipine is a selective inhibitor of the IDH2 enzyme. IDH2 is not only involved in a variety of cellular activities, including cell adaptation to hypoxic environments, histone demethylation and DNA modification, but also plays an indispensable role in the Krebs/citric acid cycle. It can catalyze the oxidative decarboxylation of isocitrate into α-ketoglutarate. But when the IDH2 enzyme mutates, it acquires a new function, reducing α-KG to the 2-hydroxyglutarate (R) enantiomer. This change will further affect the methylation status of DNA and histones, disrupt normal gene expression, and hinder the differentiation of hematopoietic progenitor cells.

Ensidipine can specifically target certain mutants of IDH2, such as R140Q, R172S and R172K, and its inhibitory effect on these mutants is much higher than that on the normal wild-type enzyme. By inhibiting these mutant IDH2 enzymes, ensidipine can effectively reduce intracellular 2-hydroxyglutarate (2-HG) levels, thereby promoting normal differentiation and proliferation of bone marrow cells.

It is worth emphasizing that ensidipine is highly specific for mutatedIDH2 but has no significant effect on normal, unmutated IDH2 enzyme. This feature significantly improves the safety and pertinence of its treatment. In addition, the inhibitory effect of ensidipine on IDH2 is reversible, which means that after stopping the drug, the activity of the IDH2 enzyme can be gradually restored, which helps to reduce the long-term side effects that the drug may cause.

In summary, ensidipine, with its unique mechanism of action and excellent therapeutic effect, is widely used inThe field of AML treatment has shown great potential. It not only brings new treatment hope to patients, but also highlights the important role of precision medicine in the fight against cancer.